RB1 expression	Glioblastoma	RB1 expression	Glioblastoma	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
RB1 expression	Liposarcoma	RB1 expression	Liposarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
RB1 expression	Soft Tissue Sarcoma	RB1 expression	Soft Tissue Sarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
RB1 expression	Breast Cancer	RB1 expression	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
RB1 expression	Prostate Cancer	RB1 expression	Prostate Cancer	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
RB1 expression	Hepatocellular Cancer	RB1 expression	Hepatocellular Cancer	lenvatinib + ribociclib Sensitive: D – Preclinical lenvatinib + ribociclib Sensitive : D	lenvatinib + ribociclib Sensitive: D – Preclinical lenvatinib + ribociclib Sensitive : D
RB1 expression	Hepatocellular Cancer	RB1 expression	Hepatocellular Cancer	lenvatinib + abemaciclib Sensitive: D – Preclinical lenvatinib + abemaciclib Sensitive : D	lenvatinib + abemaciclib Sensitive: D – Preclinical lenvatinib + abemaciclib Sensitive : D

RB1 expression

Associations